Bergen, Norway, 17 November 2021 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 9 November
2021 where the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with the exercise
of options pursuant to the Company's share option program. A total of 70,000
options were exercised and 70,000 new shares were issued at an average
subscription price of NOK 15.00 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 8,845,525.50 divided into 88,455,255 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.